{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:59:41Z","timestamp":1773266381863,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier","isbn-type":[{"value":"9780323898836","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.mcb.2024.11.006","type":"book-chapter","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T15:46:53Z","timestamp":1737128813000},"page":"115-141","source":"Crossref","is-referenced-by-count":2,"title":["PD-L1 expression in multiple myeloma myeloid derived suppressor cells"],"prefix":"10.1016","member":"78","reference":[{"issue":"40","key":"10.1016\/bs.mcb.2024.11.006_bb0010","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1021\/acs.biochem.7b00655","article-title":"The too many faces of PD-L1: A comprehensive conformational analysis study","volume":"56","author":"Ahmed","year":"2017","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/bs.mcb.2024.11.006_bb0015","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.mcb.2024.11.006_bb0020","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129353","article-title":"Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer","volume":"5","author":"Bar","year":"2020","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/bs.mcb.2024.11.006_bb0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nbt.4314","article-title":"Dimensionality reduction for visualizing single-cell data using UMAP","volume":"37","author":"Becht","year":"2019","journal-title":"Nature Biotechnology"},{"issue":"25","key":"10.1016\/bs.mcb.2024.11.006_bb0030","doi-asserted-by":"crossref","first-page":"37931","DOI":"10.18632\/oncotarget.9270","article-title":"Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma","volume":"7","author":"Binsfeld","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/bs.mcb.2024.11.006_bb0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.soncn.2017.05.012","article-title":"Pathobiology and diagnosis of multiple myeloma","volume":"33","author":"Brigle","year":"2017","journal-title":"Seminars in Oncology Nursing"},{"issue":"8","key":"10.1016\/bs.mcb.2024.11.006_bb0040","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.bbmt.2019.04.005","article-title":"A phase 2 study of Pembrolizumab during Lymphodepletion after autologous hematopoietic cell transplantation for multiple myeloma","volume":"25","author":"D\u2019Souza","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"22","key":"10.1016\/bs.mcb.2024.11.006_bb0045","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2015-03-632919","article-title":"Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy","volume":"126","author":"Dhodapkar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2024.11.006_bb0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-030-35723-8_8","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment","volume":"1224","author":"Dysthe","year":"2020","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"18","key":"10.1016\/bs.mcb.2024.11.006_bb0055","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2006.08.5829","article-title":"Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine","volume":"25","author":"Filipazzi","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/bs.mcb.2024.11.006_bb0060","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 Immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"Journal of Experimental Medicine"},{"issue":"3","key":"10.1016\/bs.mcb.2024.11.006_bb0065","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived-suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nature Reviews. Immunology"},{"issue":"8","key":"10.1016\/bs.mcb.2024.11.006_bb0070","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/intimm\/dxq049","article-title":"PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1","volume":"22","author":"Ghiotto","year":"2010","journal-title":"International Immunology"},{"issue":"15","key":"10.1016\/bs.mcb.2024.11.006_bb0075","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"G\u00f6rg\u00fcn","year":"2013","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2024.11.006_bb0080","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4939-9055-9_8","article-title":"Characterization of site-specific N-glycosylation","volume":"1934","author":"Hev\u00e9r","year":"2019","journal-title":"Methods in Molecular Biology"},{"issue":"11","key":"10.1016\/bs.mcb.2024.11.006_bb0085","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO Journal"},{"issue":"1","key":"10.1016\/bs.mcb.2024.11.006_bb0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0165-2478(02)00142-6","article-title":"Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues","volume":"84","author":"Ishida","year":"2002","journal-title":"Immunology Letters"},{"issue":"6","key":"10.1016\/bs.mcb.2024.11.006_bb0095","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/stem.140632","article-title":"Regulation of T cell apoptosis via T cell receptors and steroid receptors","volume":"14","author":"Iwata","year":"1996","journal-title":"Stem Cells"},{"issue":"1","key":"10.1016\/bs.mcb.2024.11.006_bb0100","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/leu.2017.272","article-title":"Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy","volume":"32","author":"Kelly","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/bs.mcb.2024.11.006_bb0105","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI122216","article-title":"Peptide-based PET quantifies target engagement of PD-L1 therapeutics","volume":"129","author":"Kumar","year":"2019","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/bs.mcb.2024.11.006_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nature Reviews Disease Primers"},{"issue":"7","key":"10.1016\/bs.mcb.2024.11.006_bb0115","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1158\/1078-0432.CCR-19-0267","article-title":"PD-1 blockade reinvigorates bone marrow CD8+ T cells from patients with multiple myeloma in the presence of TGFb inhibitors","volume":"26","author":"Kwon","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1016\/bs.mcb.2024.11.006_bb0120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nature Immunology"},{"issue":"6","key":"10.1016\/bs.mcb.2024.11.006_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24061190","article-title":"Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology","volume":"24","author":"Lee","year":"2019","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/bs.mcb.2024.11.006_bb0130","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","article-title":"Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1\/PD-L1 therapeutic efficacy","volume":"36","author":"Lee","year":"2019","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/bs.mcb.2024.11.006_bb0135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of triple-negative breast Cancer cells by targeting glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.mcb.2024.11.006_bb0140","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li","year":"2016","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/bs.mcb.2024.11.006_bb0145","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.15946","article-title":"Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: Phase I KEYNOTE-023 study","volume":"186","author":"Mateos","year":"2019","journal-title":"British Journal of Haematology"},{"key":"10.1016\/bs.mcb.2024.11.006_bb0150","series-title":"UMAP: Uniform manifold approximation and projection for dimension reduction","author":"Mcinnes","year":"2020"},{"issue":"4","key":"10.1016\/bs.mcb.2024.11.006_bb0155","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma","volume":"130","author":"Minnie","year":"2020","journal-title":"Journal of Clinical Investigation"},{"issue":"10","key":"10.1016\/bs.mcb.2024.11.006_bb0160","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/bs.mcb.2024.11.006_bb0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019004537","article-title":"Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma","volume":"136","author":"Perez","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2024.11.006_bb0170","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ymeth.2017.12.012","article-title":"No lyse no wash flow cytometry for maximizing minimal sample preparation","volume":"134\u2013135","author":"Petriz","year":"2018","journal-title":"Methods"},{"issue":"7","key":"10.1016\/bs.mcb.2024.11.006_bb0175","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.1203373","article-title":"Myeloid derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow","volume":"190","author":"Ramachandran","year":"2013","journal-title":"Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.mcb.2024.11.006_bb0180","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.tranon.2020.100969","article-title":"Unmasking the expression of PD-L1 in myeloid derived suppressor cells: A case study in lung cancer to discover new drugs with specific on-target efficacy","volume":"14","author":"Rico","year":"2021","journal-title":"Translational Oncology"},{"issue":"4","key":"10.1016\/bs.mcb.2024.11.006_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100883","article-title":"Flow-cytometry-based protocols for human blood\/marrow immunophenotyping with minimal sample perturbation","volume":"2","author":"Rico","year":"2021","journal-title":"STAR Protocols"},{"issue":"1","key":"10.1016\/bs.mcb.2024.11.006_bb0190","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"3","key":"10.1016\/bs.mcb.2024.11.006_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030601","article-title":"Immunotherapy in multiple myeloma","volume":"9","author":"Soekojo","year":"2020","journal-title":"Cells"},{"issue":"16","key":"10.1016\/bs.mcb.2024.11.006_bb0200","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-04-2672","article-title":"Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia","volume":"11","author":"Tamura","year":"2005","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/bs.mcb.2024.11.006_bb0205","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s13238-017-0412-8","article-title":"Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab","volume":"9","author":"Tan","year":"2018","journal-title":"Protein & Cell"},{"issue":"7","key":"10.1016\/bs.mcb.2024.11.006_bb0210","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1084\/jem.193.7.839","article-title":"B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells","volume":"193","author":"Tseng","year":"2001","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/bs.mcb.2024.11.006_bb0215","first-page":"2579","article-title":"Visualizing Data using t-SNE","volume":"9","author":"Van Der Maaten","year":"2008","journal-title":"Journal of Machine Learning Research"},{"issue":"7","key":"10.1016\/bs.mcb.2024.11.006_bb0220","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry. Part A: The Journal of the International Society for Analytical Cytology"},{"key":"10.1016\/bs.mcb.2024.11.006_bb0225","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/leu.2012.113","article-title":"Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow","volume":"26","author":"Van Valckenborgh","year":"2012","journal-title":"Leukemia"},{"issue":"41","key":"10.1016\/bs.mcb.2024.11.006_bb0230","doi-asserted-by":"crossref","first-page":"43992","DOI":"10.18632\/oncotarget.6083","article-title":"The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/bs.mcb.2024.11.006_bb0235","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00262-014-1646-4","article-title":"Tumor-induced CD14+HLA-DR\u2212\/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients","volume":"64","author":"Wang","year":"2015","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"26","key":"10.1016\/bs.mcb.2024.11.006_bb0240","doi-asserted-by":"crossref","first-page":"42414","DOI":"10.18632\/oncotarget.17123","article-title":"Type I\u03b3 phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-\u03baB","volume":"8","author":"Xue","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/bs.mcb.2024.11.006_bb0245","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","article-title":"Expression of programmed death 1 ligands by murine T cells and APC","volume":"169","author":"Yamazaki","year":"2002","journal-title":"The Journal of Immunology"},{"issue":"8","key":"10.1016\/bs.mcb.2024.11.006_bb0250","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41422-018-0060-4","article-title":"Exosomal PD-L1 harbors active defense function to suppress t cell killing of breast cancer cells and promote tumor growth","volume":"28","author":"Yang","year":"2018","journal-title":"Cell Research"},{"issue":"1","key":"10.1016\/bs.mcb.2024.11.006_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2020-001698","article-title":"Mechanisms underlying low-clinical responses to PD-1\/PD-L1 blocking antibodies in immunotherapy of cancer: A key role of exosomal PD-L1","volume":"9","author":"Yin","year":"2021","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/bs.mcb.2024.11.006_bb0260","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): A randomised, open-label, phase 3 trial","volume":"6","author":"Zafar Usmani","year":"2019","journal-title":"The Lancet Haematology"},{"issue":"8","key":"10.1016\/bs.mcb.2024.11.006_bb0265","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/0008-5472.CAN-04-4505","article-title":"Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion","volume":"65","author":"Zea","year":"2005","journal-title":"Cancer Research"}],"container-title":["Methods in Cell Biology","Flow Cytometry in Immuno-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X24002437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X24002437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:08:44Z","timestamp":1759248524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091679X24002437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780323898836"],"references-count":52,"URL":"https:\/\/doi.org\/10.1016\/bs.mcb.2024.11.006","relation":{},"ISSN":["0091-679X"],"issn-type":[{"value":"0091-679X","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}